MiNK Therapeutics, Inc.

$INKT·$60M·Biotechnology·Healthcare

——

Mentions · last 7 days

Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

Industry overviewAI analysis

Where Biotechnology sits in its cycle right now — and what that implies for $INKT.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition is the dominant structural driver — the 'next phase' of obesity drugs (oral formulations, differentiated mechanisms) is reshaping clinical bets for NVO competitors. Gene editing (CRSP, BEAM, NTLA, PRME) is transitioning from clinical to commercial-maturation phase with Casgevy scaling; oncology binary events (IBRX, ALLO, KURA) define the near-term calendar.

Top industry ETF

$IBBiShares Biotechnology ETF

+2.4%YTD

+38.3%1Y

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA $ALLO $HUMA $QURE $ALT $IBRX $PRME $BHVN

Voices on X · last 7 days

No standout posts about $INKT on X in the last 7 days.